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Abstract
Background: Circulating tumors cells (CTCs) are considered an early step towards
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metastasis and have been linked to poor prognosis in several types of cancer. CTCs
in squamous cell carcinoma of the head and neck (SCCHN) have an unclear role.
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Methods: In this prospective study, patients with locally advanced or metastatic
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SCCHN had CTC counts assessed before starting systemic treatment using the Cel-
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lSearch System. Select cases also had sequential CTC evaluation. Presence of CTCs
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was correlated with patient characteristics and outcomes.
Results: Forty-eight patients enrolled, and 36 had evaluable clinical data and baseline
CTC counts. Twenty-five patients had locally advanced disease (LAD) and 11 had
metastatic disease. ≥1 CTCs were detected in six patients with LAD (24%) and four
with metastatic disease (36%). On univariate analysis, smoking was associated
with CTCs.
Conclusion: CTCs are not associated with prognosis in patients with LAD and metastatic disease; however, they are present in this patient population, and ≥1 CTCs is
associated with a history of smoking.
Level of evidence: 1b; individual prospective cohort study.
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papillomavirus (HPV) status, smoking or alcohol history, and lymph
node involvement.3 Despite advances in the treatment for these

Squamous cell carcinoma of the head and neck (SCCHN) accounts for

patients, long-term disease-free and overall survival remains poor—

approximately 5% of newly diagnosed cancer cases, equaling roughly

approximately 40% to 60% of patients develop local recurrences and

644 000 cases and over 350 000 cancer deaths worldwide each

20% to 30% are diagnosed with metastatic disease.1,2

1,2

year.
ease

Patients typically present with locoregionally advanced dis-

(LAD),

and

prognosis

is

associated

with

age,

human

Circulating tumor cells (CTCs) and their clusters, circulating tumor
microemboli (CTM), (defined as ≥3 CTCs) are detached tumor cells
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from the primary or metastatic sites that infiltrate into the lymphatic

progression or loss to follow-up, and OS is the time from initiation of

and circulatory system. In the context of localized disease, CTCs and

treatment to death or loss to follow-up. Disease burden was assessed

CTMs are considered an early step towards metastatic spread. When

using clinical notes and imaging studies taken for standard of

present in peripheral blood, they correlate with poor prognoses in

treatment.

breast, gastric, and prostate cancer.4-8
In patients with regionally advanced or metastatic SCCHN, CTCs
have been found in 18% to 33% of patients9,10; other studies have

2.2
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Isolation and enumeration of CTCs

demonstrated that CTCs are found independently of T-stage and HPV
status.11,12 However, CTCs have an unclear impact on prognosis.

Blood samples were collected before, during, and after treatment.

Some studies have reported that CTCs correlate with reduced

Fresh, unrefrigerated peripheral blood samples were processed within

disease-free survival, progression-free survival (PFS) and overall sur-

96 hours of collection using the CellSearch System (Huntingdon

vival (OS),10,13,14 including one study of 53 patients with recurrent or

Valley, Pennsylvania). Briefly, samples were immunomagnetically

metastatic SCCHN that found CTCs were associated with lower PFS

enriched for CTCs with anti-EpCAM conjugated magnetic beads and

and OS.10 Another study of 73 patients with LAD found that a

subsequently

stained

with

immunofluorescent

antibodies

to

0

decrease in CTC count during treatment suggested nonprogressive

cytokeratins 8, 18, and 19 and CD45 and a 4 ,6-diamidino-2-phenyl-

disease.15 Others have found that CTCs did not correlate to out-

indole (DAPI) nuclear stain. Carcinoma cells were identified in a semi-

comes.9,16 More research is needed to clarify the prognostic value of

automated fashion as cells positive for cytokeratin, negative for

CTCs in SCCHN, which is the goal of this study.

CD45, and fulfilling the predefined morphologic criteria of the food

In this prospective pilot study, we enrolled 48 patients with

and drug administration (FDA)-cleared in vitro diagnostic test. All sam-

locally advanced or metastatic SCCHN and collected peripheral blood

ples were reviewed by a trained pathologist (A. C. L.). Results were

samples before starting systemic treatment. Select patients also had

reported in number of CTCs identified per 7.5 mL of whole blood.

sequential blood draws. Patients had samples analyzed by CellSearch,
which uses upregulated epithelial cell adhesion molecule (EpCAM) to
identify potential CTCs and further stratifies them based on cellular

2.3
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Statistical analysis

markers. We used this technology as it is established that EpCAM is
upregulated in many carcinomas, including SCCHN.17,18

Fisher's exact tests, likelihood ratios, and Mann-Whitney U tests were
used in univariate analysis to determine factors associated with presence of CTCs. Statistical analyses were performed using SPSS version

2

METHODS

|

2.1

24 (IBM; Armonk, NY).

Patient eligibility and demographics

|

3
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The Institutional Review Board at Dana-Farber/Brigham and
Women's Cancer Center approved the research protocol, and all

Forty-eight patients were enrolled, but one patient had inaccessible

accrued patients signed written informed consent prior to enrollment.

medical records and was not included in analysis. Forty-seven patients

Eligible

and

(44 men, 3 women), with a median age of 55.5 (24-66), enrolled from

locoregionally advanced or distant metastatic (stage III or IV, AJCC

October 2011 to October 2015. Of those with known HPV status, 30

seventh edition) disease by imaging, were receiving treatment at

patients had HPV (+) disease and 5 had HPV (−) disease. Twenty-

Dana-Farber Cancer Institute (DFCI), and had an Eastern Cooperative

three patients had a significant alcohol use history, defined as ≥5

patients

had

pathologically

confirmed

SCCHN

Oncology Group (ECOG) performance status of 2 or less. Patients

drinks/week, and 20 had a significant smoking history, defined as ≥10

treated outside of DFCI or without tumor tissue available were

pack-years. Thirty-three patients had LAD, and most received cisplatin

excluded from the study.

or carboplatin with definitive intensity modulated radiation therapy

Prior to enrollment, patients who consented to the study had pre-

for their initial treatment (n = 31). Fourteen patients had metastatic

viously been assigned treatment by their treating oncologists to one

disease and received varying systemic treatment regimens (Table 1).

of

The median follow-up was 35.5 months for the cohort.

three

regimens:

sequential

induction

followed

by

chemoradiotherapy (CRT), concurrent CRT, or systemic treatment for

Of the 47 patients, 36 (75%) had a successful CTC assessment

distant metastatic disease, which were also the three cohorts in this

prior to the start of treatment and clinical data; 8 patients never

study. Blood samples were collected based on cohort: patients with

underwent CTC draw, 1 patient withdrew consent from the study

LAD and metastatic cancer had 7.5 mL of whole blood collected

prior to capturing outcome data, and two patients had incomplete

before starting treatment. Some patients also had sequential blood

CTC analysis due to poor sample quality and CellSearch failure,

draws throughout treatment and during follow-up. Patient demo-

respectively. Twenty-five patients had LAD and 11 had metastatic dis-

graphics were collected and deidentified, and subjects were followed

ease. Most patients had primary lesions in the oropharynx (n = 23)

for PFS and OS. PFS is the time from initiation of treatment to disease

and HPV (+) disease (n = 23). In this cohort, 19 patients had a smoking
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TABLE 1

Consented patient characteristics
All patientsa
(%) (n = 47)

Induction arm
(%) (n = 15)

55.0 (24-72)

55 (24-66)

52 (30-72)

44 (93.6%)

13 (86.7%)

17 (94.4%)

14 (100.0%)

3 (6.4%)

2 (13.3%)

1 (5.6%)

0 (0.0%)

Positive

30 (85.7%)

12 (92.3%)

10 (90.9%)

8 (72.7%)

Negative

5 (14.3%)

1 (7.7%)

1 (9.1%)

3 (27.3%)

<10 pack-years

26 (56.5%)

9 (60.0%)

12 (70.6%)

5 (35.7%)

≥10 pack-years

20 (43.5%)

6 (40.0%)

5 (29.4%)

9 (64.3%)

≥5 drinks/wk

23 (52.3%)

8 (57.1%)

7 (41.2%)

8 (61.5%)

<5 drinks/wk

21 (47.7%)

6 (42.9%)

10 (58.8%)

5 (38.5%)

Median age at blood draw (range), y

CRT arm
(%) (n = 18)

Metastatic arm
(%) (n = 14)
60.5 (50-68)

Gender
Male
Female
b

HPV status

Smoking historyc

Alcohol history

d

Most recent systemic treatment prior to CTC draw
Cisplatin

19 (40.4%)

3 (20.0%)

15 (83.3%)

1 (7.1%)

Carboplatin

15 (31.9%)

10 (66.7%)

3 (16.7%)

2 (14.3%)

Cetuximab and carboplatin

2 (4.3%)

2 (13.3%)

Nivolumab

2 (4.3%)

-

-

2 (14.3%)

Pembrolizumab

2 (4.3%)

-

-

2 (14.3%)

EXTREME

1 (2.1%)

-

-

1 (7.1%)

-

-

Cetuximab and gemcitabine

1 (2.1%)

-

-

1 (7.1%)

5-FU and leucovorin

1 (2.1%)

-

-

1 (7.1%)

Vinorelbine

1 (2.1%)

-

-

1 (7.1%)

Taxotere

1 (2.1%)

-

-

1 (7.1%)

Gemcitabine

1 (2.1%)

-

-

1 (7.1%)

Cetuximab

1 (2.1%)

-

-

1 (7.1%)

Median follow-up time from study entry
(range), mo

35.5 (2-71)

58 (13-71)

39.0 (4-64)

6 (2-20)

Abbreviations: 5-FU, 5-fluorouracil; CRT, concurrent radiotherapy; CTC = circulating tumor cells; HPV, human papillomavirus.
One patient had an inaccessible medical record and was excluded from analysis.
b
A total of 12 patients (2 patients in induction arm, 7 patients in CRT arm, and 3 patients in metastatic arm) had unknown HPV status.
c
One patient in the CRT arm had unknown smoking history.
d
A total of three patients (one patient in induction arm, one patient in CRT arm, and one patient in metastatic arm) had unknown alcohol history.
a

history <10 pack years, and 19 had <5 alcoholic drinks/week. Baseline

once. Timing of blood draws and number (range: 2-12) varied. Neither

CTCs were detected in six patients with LAD and four with metastatic

median PFS nor OS were significantly associated with CTCs (Table 4).

disease and had varying amounts (range = 1-9). Primary location, T-

Within this cohort, three patients had CTMs; one patient had CTMs

stage, N-stage, disease burden, HPV association, median PFS, and

during treatment, and two patients had CTMs before treatment. The

median OS were not associated with ≥1 CTCs. Significant smoking

two patients who had CTMs before treatment had metastatic disease

history (P = .002) was associated with ≥1 CTCs—10 patients had

and CTCs ≥2 at multiple time points. The patients died 2 and 6 months

detectable CTCs at baseline and 9 had a significant smoking history

after the baseline draw, respectively. Notably, the former patient had

(Table 2). Of these nine patients, three patients also had a significant

170 CTCs 4 days before death.

alcohol history. Comparing LAD and metastatic SCCHN PFS and OS
with CTCs did not demonstrate a significant correlation (Table 3).
Separately, 18 patients had sequential CTC blood draws at base-

4

|

DI SCU SSION

line and during or after treatment. Eleven patients never had ≥1 CTCs,
while seven did. Of the seven patients, three patients had CTCs

We conducted a prospective pilot study investigating the effect of

detected once, while four patients had CTCs detected more than

CTCs on PFS and OS in patients with locally advanced or metastatic

1066

HARRIS ET AL.

0 CTCs (%) (n = 26)

≥ 1 CTCs (%) (n = 10)

P value

T A B L E 2 Factors associated with
baseline CTCs

Primary tumor location
Oropharynx

19 (73.1%)

4 (40.0%)

7 (26.9%)

6 (60.0%)

T1

5 (20.8%)

2 (25.0%)

T2

6 (25.0%)

4 (50.0%)

T3

9 (37.5%)

1 (12.5%)

T4

4 (16.7%)

1 (12.5%)

<N2b

7 (26.9%)

1 (14.3%)

≥N2b

19 (73.1%)

6 (85.7%)

Other

.119

T staginga

N staging

.449

b

.652

Disease burden at time of draw
LAD

19 (73.1%)

6 (60.0%)

7 (26.9%)

4 (40.0%)

Positive

18 (85.7%)

5 (83.3%)

Negative

3 (14.3%)

1 (16.7%)

<10 pack-years

18 (69.2%)

1 (10.0%)

≥10 pack-years

8 (30.8%)

9 (90.0%)

15 (62.5%)

4 (40.0%)

Metastatic disease

.454

HPV statusc
1

Smoking history
.002

Alcohol historyd
<5 drinks/wk
≥5 drinks/wk
Median OSe (range), mo
f

Median PFS (range), mo

9 (37.5%)

.276

6 (60.0%)

32.10 (3-72)

30.30 (1-70)

.337

28.00 (1-71)

28.00 (1-70)

.614

Abbreviations: CTC, circulating tumor cells, HPV, human papillomavirus; LAD, locally advanced disease;
OS, overall survival, PFS, progression-free survival.
a
Two patients in the “0 CTCs” group and two patients in the “CTCs observed” group had unknown Tstaging.
b
Three patients in the “≥1 CTCs group” had unknown N staging.
c
Five patients in the “0 CTCs” group and four patients in the “CTCs observed” group had unknown HPV
status.
d
Two patients in the “0 CTCs” group had unknown alcohol history.
e
PFS is until disease progression or last available follow-up.
f
OS is until death or last available follow-up.

Locally advanced disease

0 CTCs (n = 19)

≥1 CTCs (n = 6)

P value

Median PFSa (range), mo

41.00 (4-71)

38.50 (25-69)

.975

40.30 (26-70)

.555

b

Median OS (range), mo

44.40 (5-72)

Metastatic disease

0 CTCs (n = 7)

a

Median PFS (range), mo
b

Median OS (range), mo

≥1 CTCs (n = 4)

P value

4.00 (1-7)

2.50 (1-19)

.927

11.13 (3-21)

5.37 (1-19)

.412

Abbreviations: CTC, circulating tumor cells; OS, overall survival; PFS, progression-free survival.
a
PFS is until disease progression or last available follow-up.
b
OS is until death or last available follow-up.

T A B L E 3 Disease burden at time of
baseline CTC draw vs PFS and OS
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TABLE 4

CTCs in patients with sequential draws vs PFS and OS
0 CTCs (n = 11)

≥1 CTCs (n = 7)

P value

Median PFS (range), mo

31.00 (1-71)

13.00 (1-69)

.126

Median OSb (range), mo

60.73 (3-72)

13.73 (1-70)

.285

a

Abbreviations: CTC, circulating tumor cells; OS, overall survival; PFS, progression-free survival.
a
PFS is until disease progression or last available follow-up.
b
OS is until death or last available follow-up.

SCCHN. Forty-eight patients enrolled in this study and 36 patients

detection by CellSearch, smoking was similarly found not to be associ-

had evaluable CTCs with correlating clinical data. Of the 36 patients,

ated with smoking.38,39 Although these are contradictory to our find-

CTCs were detected in six patients with LAD and four patients with

ings, they suggest that the differences in detection methods and

metastatic disease (24% and 36%, respectively). A significant smoking

carcinoma contribute to the variability.

history was associated with CTCs on univariate analysis, while tumor
stage and other known prognostic markers were not.

The lack of association with PFS and OS in this study raises
the question as to whether CellSearch in SCCHN selects the most

CTCs have been studied in various cancers, and these studies sug-

prognostic population. Recently, new technologies have allowed

gest that increased CTCs are associated with a poorer prognosis. In

detection of CTCs that are not dependent on EpCAM and have

breast cancer, CTC-positive patients (≥5 CTCs/7.5 mL) have decreased

shown promise.40 With the current data available on CellSearch on

and in a study of 216 patients with ovarian cancer, ≥2

patients with SCCHN, it seems that other modalities should be

CTCs at baseline predicted increased risk for both progression and

examined. Moreover, Nicolazzo et al describe the challenges with

death.20 The majority of findings in lung cancer that analyzed CTCs

CellSearch and how subpopulations of CTCs with lower expression

using CellSearch, both in nonsmall cell lung cancer and small cell lung

levels of EpCAM are worth investigating, especially since CTCs

19

PFS and OS,

21

cancer, have found that increased CTCs predict poorer prognosis.

Thus far, few studies have been published about the impact of CTCs

from patients with SCCHN detected by CellSearch do not have
prognostic value.41

in head and neck cancer. One study of 53 patients with recurrent/meta-

This study had limitations—our low enrollment and heterogene-

static head and neck cancer stratified patients with ≥2, 1, and 0 CTCs at

ity of disease weaken our conclusions. Also, treatment was not stan-

baseline, and found a significant difference in PFS and OS between the

dardized within cohorts. Additionally, some patients had more

cohorts.10 Similar to breast cancer, ovarian cancer, and other cancers,

sequential blood draw results than others, and several patients did

increased CTCs seem to predict a worse prognosis, although this must

not meet the endpoints of the study. Timing of blood draws in rela-

be validated in SCCHN. In our cohort, we had two patients with ≥2

tion to treatment may have played a role in the differences in CTC

detectable CTCs at multiple time points, with one patient surviving for

counts.
Our data suggest that smoking may play a role in CTC develop-

2 months and having 170 CTCs 4 days before death.
This study found that smoking is positively associated with CTC

ment in patients with SCCHN. A homogenous study cohort with stan-

detection on univariate analysis. Smoking has many effects on cell-

dardized care, increased enrollment, and regularization of blood draws

to-cell adhesion, including downregulating E-cadherin, a tumor sup-

during and after treatment might have allowed us to establish associa-

pressor that maintains cell-cell adhesion, and promoting epithelial to

tion between CTC and other factors more firmly, and we therefore

mesenchyme transition (EMT)22-29 in various cancers including pros-

suggest further investigation to assess efficacy and predictive value of

tate, lung, and oropharyngeal squamous cell carcinoma.26,30-32 More-

CTCs in this patient population.

over, a key step in EMT is loss of E-cadherin, leading to invasive
behavior and metastasis. Tobacco smoke plays a role in this patho-
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